Morgan Stanley Expects Positive Bristol-Myers Squibb Co. (BMY) Data in Coming Weeks
Tweet Send to a Friend
Morgan Stanley analyst David Risinger reiterated an Overweight rating and $67.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) on ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
